This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A study found that children aged 6 months or younger who are not eligible for vaccination were at the highest risk for hospitalization due to SARS-CoV-2.
Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.
Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.
Hospitalization and interprofessional team management, particularly the involvement of a pharmacist, are essential in vaccination coverage for patients with diabetes.
Vaccines reduce the risk of COVID-19 infection and hospitalization, but a recent study suggests that misinformation could make adults hesitant to vaccinate children 5 to 11 years of age.
The standard advice — get your shots, get them at the same time, don’t wait too long to roll up your sleeves — is designed to maximize convenience and compliance, in a way that is manageable for the delivery enterprise, say experts familiar with the enormous effort it takes to turn vaccines into vaccinations.
A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched Thursday with $54 million in funding. Altschuler and Ziff’s relationship goes back to the mid-2010s, when Altschuler was chief executive of the well-known research hospital Children’s Hospital of Philadelphia, or CHOP.
The findings suggest a positive impact of RSV vaccination on RSV-associated hospital admission, emphasizing the importance of protection in this population.
PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides the broadest serogroup coverage of any meningococcal vaccine available in the US for meningococcal disease in individuals aged 10 to 25 years old, has been approved by the US Food and Drug Administration (FDA).
Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. . While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over.
Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR).
Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.
Is a century-old vaccine a ‘game-changer’ for COVID-19? This is especially true in the search for effective therapies to fight COVID-19, and a vaccine. In a worst-case scenario, misplaced hype could lead to a sudden rush to buy doses of the BCG vaccine. Understanding the link between COVID-19 and the BCG vaccine.
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.
This year, there are new vaccines to help at-risk populations ward off severe sickness, including that caused by RSV. Here’s what you need to know about the new FDA-approved RSV vaccine. Is there a vaccine for RSV? Not all vaccines work via the same science. Not all vaccines work via the same science. What is RSV?
The UK could be the first country to carry out a COVID-19 “challenge trial” where healthy volunteers are deliberately infected with coronavirus to test vaccines, according to press reports. That vaccine is top of the World Health Organization’s list of vaccines in clinical development, which shows there are 38 potential shots in human trials.
In the latest edition of What HCPs Think , CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. This sudden increase is due to reports of rare blood clots in recipients of the COVID-19 vaccines developed by AstraZeneca and more recently Johnson & Johnson.
A plant in Wales manufacturing the AstraZeneca COVID-19 vaccine was evacuated on the advice of the authorities today after it was sent a suspicious package. The contract covers production of 100 million doses of the AZ vaccine. Wockhardt UK in Wrexham this morning received a suspicious package.
OVX836 is a universal influenza A vaccine which appears to be safe and has previously shown a preliminary signal of protection against influenza symptoms. This is a recombinant protein-based vaccine which targets the highly conserved influenza nucleoprotein (NP) and therefore potentially confers broad-spectrum protection against influenza.
AstraZeneca and Oxford University have started dosing patients in a trial of a new version of their COVID-19 vaccine that is designed to target the beta or South African variant of the SARS-CoV-2 virus. The post AZ starts phase 2/3 trial of new-variant COVID-19 vaccine appeared first on. The beta variant – also known as B.1.351
Moderna disclosed Monday that it plans to price its Covid-19 vaccine at anywhere from $110 to $130 per dose when the company pivots from a focus on government contracts to commercial distribution efforts. The timing was not disclosed, but the company is holding talks with hospitals, pharmacy chains and pharmacy benefit managers.
The UK should introduce routine vaccination for respiratory syncytial virus (RSV) to protect babies and older adults, the Joint Committee on Vaccination and Immunisation (JCVI) has recommended. The post JCVI backs RSV routine vaccination for babies and older adults in the UK appeared first on Hospital Pharmacy Europe.
The Joint Committee on Vaccination and Immunisation (JCVI) has advised offering Covid booster vaccinations in spring and autumn 2023 for patients deemed to be at high risk. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year.
5-adapted-bivalent COVID-19 vaccine demonstrated a substantial increase in antibody response above pre-booster levels. 5-adapted bivalent COVID-19 vaccine showed a substantial increase in neutralising antibody response according to a press release by the joint manufacturers Pfizer and BioNTech. The Omicron BA.4/BA.5-adapted-bivalent
A 90-year-old woman has become the first person given a COVID-19 vaccine as part of the UK’s mass vaccination programme. Margaret Keenan was given the injection at 06:31 this morning at University Hospitals Coventry and Warwickshire NHS Trust. The post First COVID-19 vaccinations begin in UK hospitals appeared first on.
Pharmacists have been central to vaccine distribution since the COVID-19 pandemic, and as viruses spread, they must continue urging patients to stay updated on vaccinations to prevent severe illness and reduce hospitalizations.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
551 
Let's personalize your content